ERBB2 and neoplasm: Most trials that studied the correlation of tumor infiltrating lymphocytes (TILs) and response to HER2-targered therapy are in the chemotherapy setting, which could be a confounding factor in judging the predictive value of TILs on the response to anti-HER2 therapy.